Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.
References
Monoclonal antibodies
Experimental cancer drugs
{{antineoplastic-drug-stub